19th Ave New York, NY 95822, USA

Grup de Cèl·lules Mare i Càncer

Stem Cells & Cancer Group VHIO

El Grup de Cèl·lules Mare i Càncer d’Héctor G. Palmer estudia els mecanismes que permeten que els tumors eludeixin els tractaments eficaços i progressin a estadis avançats.

El seu equip utilitza enfocaments multiòmics per revelar alteracions inesperades relacionades amb fenotips tumorals i unicel·lulars. Combina l’edició de gens (CRISPR/Cas) amb la bioquímica de senyalització clàssica en línies cel·lulars del càncer, així com ratolins modificats genèticament, organoides i xenoempelts derivats de pacients (PDX), per estudiar la rellevància funcional d’aquestes alteracions identificades recentment en la resposta dels pacients a les teràpies.

El grup també forma part d’un grup de treball multidisciplinari global que incorpora oncòlegs mèdics, cirurgians, radiòlegs i infermeres. Aquesta estreta col·laboració permet traslladar ràpidament els resultats del laboratori a la clínica.

Héctor G. Palmer
Cap de grup
Isabel_Puig
Isabel Puig Borrell
Investigador sènior
Jordi-Martinez-Quintanilla
Jordi Martínez-Quintanilla Quintanilla
Investigador sènior

Les línies de recerca principals són:

  • Latència de les cèl·lules tumorals
    L’estudi de la intrigant biologia de la latència de les cèl·lules canceroses responsable de la quimioresistència, la formació de malaltia residual mínima i la recaiguda dels pacients.
    L’equip va descobrir una xarxa epigenètica central que regeix la latència de les cèl·lules tumorals (J Clin Invest. 2018) i ara està investigant més profundament la funció de TET2, DPPA3 i altres factors epigenètics i de transcripció que regeixen la latència. És important destacar que està avançant ràpidament en el desenvolupament de fàrmacs que modulen els impulsors de la latència, inclòs TET2, i en la definició de nous biomarcadors per detectar cèl·lules tumorals inactives (CTI) resistents a la quimioteràpia.
  • Resposta als fàrmacs dirigits a dianes
    Aquest grup treballa en estreta col·laboració amb oncòlegs i empreses farmacèutiques per identificar els mecanismes moleculars responsables de la sensibilitat o resistència a fàrmacs que bloquegen Wnt/beta-catenina, Notch, PI3K/AKT, EGFR/LGR5 o els senyals oncogènics BRAF/MEK/ERK(Nat Med. 2012; Clin Can Res. 2014; Clin Can Res. 2019). Basant-se en els seus descobriments, l’equip està dissenyant noves proves de preselecció per a la inscripció guiada genèticament de pacients a assaigs clínics. Els descobriments estan ajudant de manera crucial a definir noves combinacions racionals de fàrmacs per tractar els pacients oncològics amb malaltia progressiva.
  • Models de càncer preclínics avançats
    El grup també està ampliant i caracteritzant les seves col·leccions de PDX (CCR, neuroendocrí i pseudomixoma peritoneal) i millorant-ne el potencial per avaluar l’eficàcia dels fàrmacs i la metàstasi mitjançant la injecció ortotòpica i l’obtenció d’imatges en viu (TC, PET i ecografia). Finalment, els investigadors estan desenvolupant projectes ambiciosos a través del Consorci EuroPDX (pàgina 176), una col·laboració que va cofundar el VHIO i incorpora els principals grups de referència que treballen amb PDX a Europa.

Figura: Les cèl·lules tumorals inactives quimioresistents (nuclis verds) s’amaguen dins de nínxols hipòxics (vermells) en carcinomes en creixement.

Stem Cells & Cancer Group VHIO
Cap de grup
Héctor G. Palmer
Investigadors sènior
Isabel Puig
Jordi Martínez-Quintanilla
Becaris postdoctorals
Oriol Arqués
Estudiants de doctorat
Candida Salvans Gorjón
Alex Mur
Lorena Ramirez
Tècnics
Laia Cabellos
Irene Chicote
Jordi Vergés San Jaime
Debora Cabot
Anna Maria Alcántara

Publicacions científiques més rellevants

  • Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O’Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021 Jan;53(1):86-99.
  • Harmston N, Lim JYS, Arqués O, Palmer HG, Petretto E, Virshup DM, Madan B. Widespread Repression of Gene Expression in Cancer by a Wnt/β-Catenin/MAPK Pathway. Cancer Res. 2021 Jan 15;81(2):464-475.
  • Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen IA, Langerud J, Røsok B, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intrapatient Pharmacotranscriptomic Heterogeneity. Clin Cancer Res. 2020 Aug 1;26(15):4107-4119.
  • Capdevila J, Arqués O, Hernández Mora JR, Matito J, Caratù G, Mancuso FM, Landolfi S, Barriuso J, Jimenez-Fonseca P, Lopez Lopez C, Garcia-Carbonero R, Hernando J, Matos I, Nuciforo P, Hernández-Losa J, Esteller M, Martínez-Cardús A, Tabernero J, Vivancos A, Palmer HG. Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clin Cancer Res. 2020 Feb 15;26(4):902-909. doi: 10.1158/1078-0432.CCR-19-1266. Epub 2019 Oct 31.
  • Capdevila J, Matos I, Mancuso FM, Iglesias C, Nuciforo P, Zafon C, Palmer HG, Ogbah Z, Muiños L, Hernando J, Villacampa G, Peña CE, Tabernero J, Brose MS, Schlumberger M, Vivancos A. Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. Mol Cancer Ther. 2020 Jan;19(1):312-317. doi: 10.1158/1535-7163.MCT-19-0211. Epub 2019 Sep 20.
  • Selenica P, Raj N, Kumar R, Brown DN, Arqués O, Reidy D, Klimstra D, Snuderl M, Serrano J, Palmer HG, Weigelt B, Reis-Filho JS, Scaltriti M. Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. Mol Oncol. 2019 Aug;13(8):1684-1692. doi: 10.1002/1878-0261.12490. Epub 2019 Jul 3.
  • Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J Clin Invest. 2018 Aug 31;128(9):3887-3905.
  • Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clin Cancer Res. 2018 Feb 15;24(4):794-806.
  • Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2017 Oct 1;28(10):2451-2457.
  • Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in cancer medicine with patient-derived xenografts. Nat Rev Cancer. 2017 Sep 15;17(10):632.
  • Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Mol Oncol. 2017 Sep;11(9):1263-1272.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Feb 1;22(3):644-56.
  • Barbáchano A, Fernández-Barral A, Pereira F, Segura MF, Ordóñez-Morán P, Carrillo-de Santa Pau E, González-Sancho JM, Hanniford D, Martínez N, Costales-Carrera A, Real FX, Palmer HG, Rojas JM, Hernando E, Muñoz A. SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150. Oncogene. 2016 Jun 9;35(23):2991-3003.
  • Jubierre L, Soriano A, Planells-Ferrer L, París-Coderch L, Tenbaum SP, Romero OA, Moubarak RS, Almazán-Moga A, Molist C, Roma J, Navarro S, Noguera R, Sánchez-Céspedes M, Comella JX, Palmer HG, Sánchez de Toledo J, Gallego S, Segura MF. BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways. Oncogene. 2016 Sep 29;35(39):5179-90.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodón J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Pálmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb; 22(3): 644-56
  • García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodriguez O, Grueso J, Anton P, Guzman M, Aura C, Nuciforo P, Jessen K, Argiles G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Pálmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin. Cancer Res. 2015 Dec; 21(24): 5499-510
  • Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horváth Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Pálmer HG, Hurlstone A, Crespo P. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell 2015 Aug; 28(2): 170-82
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortes J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 2015; 5: 8179
  • Ordóñez-Morán P, Irmisch A, Barbáchano A, Chicote I, Tenbaum S, Landolfi S, Tabernero J, Huelsken J, Muñoz A, Pálmer HG. SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer. Oncogene 2014 Apr; 33(15): 1975-85
  • Anjos-Afonso F, Currie E, Pálmer HG, Foster KE, Taussig DC, Bonnet D. CD34(-) cells at the apex of the human hematopoietic stem cell hierarchy have distinctive cellular and molecular signatures. Cell Stem Cell 2013 Aug; 13(2): 161-74
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Ramón y Cajal S, del Campo JM, Ramony Cajal S, Felip E, Tabernero J, Cortes J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 3: 3544
  • Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argiles G, Vivancos A, Tabernero J, Rojas S, Pálmer HG. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin. Cancer Res. 2013 Dec; 19(24): 6787-801

Totes les publicacions

  • Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O’Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021 Jan;53(1):86-99.
  • Harmston N, Lim JYS, Arqués O, Palmer HG, Petretto E, Virshup DM, Madan B. Widespread Repression of Gene Expression in Cancer by a Wnt/β-Catenin/MAPK Pathway. Cancer Res. 2021 Jan 15;81(2):464-475.
  • Capdevila J, Arqués O, Hernández Mora JR, Matito J, Caratù G, Mancuso FM, Landolfi S, Barriuso J, Jimenez-Fonseca P, Lopez Lopez C, Garcia-Carbonero R, Hernando J, Matos I, Paolo N, Hernández-Losa J, Esteller M, Martínez-Cardús A, Tabernero J, Vivancos A, Palmer HG. Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas.Clin Cancer Res. 2020 Feb 15;26(4):902-909. doi: 10.1158/1078-0432.CCR-19-1266. Epub 2019 Oct 31.
  • Capdevila J, Matos I, Mancuso FM, Iglesias C, Nuciforo P, Zafon C, Palmer HG, Ogbah Z, Muiños L, Hernando J, Villacampa G, Peña CE, Tabernero J, Brose MS, Schlumberger M, Vivancos A. Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial.Mol Cancer Ther. 2020 Jan;19(1):312-317. doi: 10.1158/1535-7163.MCT-19-0211. Epub 2019 Sep 20.
  • Selenica P, Raj N, Kumar R, Brown DN, Arqués O, Reidy D, Klimstra D, Snuderl M, Serrano J, Palmer HG, Weigelt B, Reis-Filho JS, Scaltriti M. Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway.Mol Oncol. 2019 Aug;13(8):1684-1692. doi: 10.1002/1878-0261.12490. Epub 2019 Jul 3.
  • Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clin Cancer Res. Epub 2017 Dec 14.
  • Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2017 Oct 1;28(10):2451-2457.
  • Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in cancer medicine with patient-derived xenografts. Nat Rev Cancer. 2017 Sep 15;17(10):632.
  • Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Mol Oncol. 2017 Sep;11(9):1263-1272.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Feb 1;22(3):644-56.
  • Barbáchano A, Fernández-Barral A, Pereira F, Segura MF, Ordóñez-Morán P, Carrillo-de Santa Pau E, González-Sancho JM, Hanniford D, Martínez N, Costales-Carrera A, Real FX, Palmer HG, Rojas JM, Hernando E, Muñoz A. SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150. Oncogene. 2016 Jun 9;35(23):2991-3003.
  • Jubierre L, Soriano A, Planells-Ferrer L, París-Coderch L, Tenbaum SP, Romero OA, Moubarak RS, Almazán-Moga A, Molist C, Roma J, Navarro S, Noguera R, Sánchez-Céspedes M, Comella JX, Palmer HG, Sánchez de Toledo J, Gallego S, Segura MF. BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways. Oncogene. 2016 Sep 29;35(39):5179-90.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodón J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Pálmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin. Cancer Res. 2016 Feb; 22(3): 644-56
  • García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodriguez O, Grueso J, Anton P, Guzman M, Aura C, Nuciforo P, Jessen K, Argiles G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Pálmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin. Cancer Res. 2015 Dec; 21(24): 5499-510
  • Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horváth Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Pálmer HG, Hurlstone A, Crespo P. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell 2015 Aug; 28(2): 170-82
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortes J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 2015; 5: 8179
  • Ordóñez-Morán P, Irmisch A, Barbáchano A, Chicote I, Tenbaum S, Landolfi S, Tabernero J, Huelsken J, Muñoz A, Pálmer HG. SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer. Oncogene 2014 Apr; 33(15): 1975-85
  • Anjos-Afonso F, Currie E, Pálmer HG, Foster KE, Taussig DC, Bonnet D. CD34(-) cells at the apex of the human hematopoietic stem cell hierarchy have distinctive cellular and molecular signatures. Cell Stem Cell 2013 Aug; 13(2): 161-74
  • Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Ramón y Cajal S, del Campo JM, Ramony Cajal S, Felip E, Tabernero J, Cortes J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 3: 3544
  • Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argiles G, Vivancos A, Tabernero J, Rojas S, Pálmer HG. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin. Cancer Res. 2013 Dec; 19(24): 6787-801
  • Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramón y Cajal S, Schwartz S, Vivancos A, Espín E, Rojas S, Baselga J, Tabernero J, Muñoz A, Pálmer HG. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat. Med. 2012 Jun; 18(6): 892-901
  • Larriba MJ, Ordóñez-Morán P, Chicote I, Martín-Fernández G, Puig I, Muñoz A, Pálmer HG. Vitamin D receptor deficiency enhances Wnt/β-catenin signaling and tumor burden in colon cancer. PLoS ONE 2011; 6(8): e23524
  • Barbáchano A, Ordóñez-Morán P, García JM, Sánchez A, Pereira F, Larriba MJ, Martínez N, Hernández J, Landolfi S, Bonilla F, Pálmer HG, Rojas JM, Muñoz A. SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene 2010 Aug; 29(34): 4800-13
  • Pálmer HG, Anjos-Afonso F, Carmeliet G, Takeda H, Watt FM. The vitamin D receptor is a Wnt effector that controls hair follicle differentiation and specifies tumor type in adult epidermis. PLoS ONE 2008; 3(1): e1483
  • Pálmer HG, Larriba MJ, García JM, Ordóñez-Morán P, Peña C, Peiró S, Puig I, Rodríguez R, de la Fuente R, Bernad A, Pollán M, Bonilla F, Gamallo C, de Herreros AG, Muñoz A. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat. Med. 2004 Sep; 10(9): 917-9
  • Pálmer HG, González-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Muñoz A. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell Biol. 2001 Jul; 154(2): 369-87
  1.  PERSIST-SEQ. Building a reproducible single-cell experimental workflow to capture tumour drug persistence. FINANCIAL ENTITY: IMI Program. Pharma Industry and UE (Horizon 2020-JTI-IMI2-2020-20-two-stage). Duration: 2021-2024. PI: Héctor G. Palmer.
  2. Targeting dormant tumor cells as a new strategy to fight cancer. PI20/00897. FINANCIAL ENTITY: Instituto de Salud Carlos III (ISCIII). Duration. 2021-2023. PI: Héctor G. Palmer.
  3. First-in-class small drug activators of TET2 for the treatment of cancer FINANCIAL ENTITY: Fundación de la Asociación Española Contra el Cáncer (AECC). Duration: 2020-2021. PI: Héctor G. Palmer.
  4. Tumor microenvironment-derived factors in localized colon cancer: clinical impact and therapeutic implications. FINANCIAL ENTITY: Fundación de la Asociación Española Contra el Cáncer (AECC). Duration: 2020-2024. PI: Héctor G. Palmer (Coordinator: Andrés Cervantes).
  5. CaixaImpulse Validate. A novel approach to enhance the therapeutic efficacy of CAR cells. FINANCIAL ENTITY: Fundación Bancaria Caixa d’Estalvis i Pensions de Barcelona. Duration: 2020-2021. PI: Carlos Galdeano.
  6. Accelerator Award. Pseudomyxoma peritonei: building a European multicentric cohort to accelerate new therapeutic perspectives. FINANCIAL ENTITY: Cancer Research UK (CRUK), Asociación Española contra el Cancer (AECC) & Associazione Italina per la Ricerca sul Cancro (AIRC). Duration: 2019-2024. PI: Héctor G. Palmer. (Consortium Coordinator: Marcello Deraco).
  7. Accelerator Award. ACRCelerate: Colorectal Cancer Stratified Medicine Network. FINANCIAL ENTITY: Cancer Research UK (CRUK), Asociación Española contra el Cancer (AECC) & Associazione Italina per la Ricerca sul Cancro (AIRC). Duration: 2018-2021. PI: Héctor G. Palmer. (Consortium Coordinator: Owen Sansom).
  8. EDIReX, EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts. #731105. FINANCIAL ENTITY: EU Horizon2020 Research and Innovation Program. Duration: 2018-2021. PI: Héctor G. Palmer. (Consortium Coordinator: Enzo Medico).
  9. FINANCIAL ENTITY: Fundación de la Asociación Española Contra el Cáncer (AECC). Duration: 2017-2021. PIs: Isabel Puig and Héctor G. Palmer
  10. ONIRIA: Mastering Cell Dormancy to Fight Cancer.
    El presente proyecto está cofinanciado por el Fondo Europeo de Desarrollo Regional. Objetivo Temático: maximise the value of our drug candidates, ensure successful funding that will finance all the preclinical development and identify additional indications where our compounds could have therapeutic value.